Tempest Plans To Report New And Updated Data From Global Randomized Combination Study Of TPST-1120 In First-Line Hepatocellular Carcinoma
Portfolio Pulse from Benzinga Newsdesk
Tempest Therapeutics is set to report new and updated data from its global randomized combination study of TPST-1120 in first-line Hepatocellular Carcinoma. The data will be released in a premarket press release on Wednesday, October 11, 2023, followed by a webcasted conference call with an associated slide presentation.
October 10, 2023 | 8:08 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
The release of new and updated data from Tempest's TPST-1120 study could potentially impact the company's stock price.
The release of new and updated data from a significant study like TPST-1120 can influence investor sentiment and potentially impact the stock price. However, the direction of the impact will depend on the results of the study.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100